Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

Background: Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.

Methods: Single nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types.

Results: We identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P < .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P < .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types.

Conclusions: CNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.

Citing Articles

Germline copy number variants and endometrial cancer risk.

Stylianou C, Wiggins G, Lau V, Dennis J, Shelling A, Wilson M Hum Genet. 2024; 143(12):1481-1498.

PMID: 39495297 PMC: 11576655. DOI: 10.1007/s00439-024-02707-9.

Comparison of the diagnostic significance of cerebrospinal fluid metagenomic next-generation sequencing copy number variation analysis and cytology in leptomeningeal malignancy.

Zhang L, Fang K, Ren H, Fan S, Wang J, Guan H BMC Neurol. 2024; 24(1):223.

PMID: 38943096 PMC: 11212224. DOI: 10.1186/s12883-024-03655-7.

FASTKD1 as a diagnostic and prognostic biomarker for STAD: Insights into m6A modification and immune infiltration.

Yang Y, Gao Y, Liu X, Huang Z, Zhang Y, Zhang Y Exp Ther Med. 2024; 28(2):305.

PMID: 38873045 PMC: 11170332. DOI: 10.3892/etm.2024.12594.

Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension.

Langlois A, Pouget J, Knight J, Chenoweth M, Tyndale R Eur J Hum Genet. 2023; 32(3):357-360.

PMID: 38097766 PMC: 10923790. DOI: 10.1038/s41431-023-01518-2.

Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.

Hartkopf A, Fehm T, Welslau M, Muller V, Schutz F, Fasching P Geburtshilfe Frauenheilkd. 2023; 83(6):653-663.

PMID: 37916183 PMC: 10617391. DOI: 10.1055/a-2074-0551.

References

Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst F . BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997; 17(3):341-5. DOI: 10.1038/ng1197-341. View

Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut J . A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018; 78(18):5419-5430. PMC: 6139053. DOI: 10.1158/0008-5472.CAN-18-0951. View

Song H, Dicks E, Ramus S, Tyrer J, Intermaggio M, Hayward J . Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol. 2015; 33(26):2901-7. PMC: 4554751. DOI: 10.1200/JCO.2015.61.2408. View

Laplana M, Royo J, Garcia L, Aluja A, Gomez-Skarmeta J, Fibla J . SIRPB1 copy-number polymorphism as candidate quantitative trait locus for impulsive-disinhibited personality. Genes Brain Behav. 2014; 13(7):653-62. DOI: 10.1111/gbb.12154. View

Rafnar T, Gudbjartsson D, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A . Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011; 43(11):1104-7. DOI: 10.1038/ng.955. View

Abel H, Larson D, Regier A, Chiang C, Das I, Kanchi K . Mapping and characterization of structural variation in 17,795 human genomes. Nature. 2020; 583(7814):83-89. PMC: 7547914. DOI: 10.1038/s41586-020-2371-0. View

Bae J, Cheong H, Kim J, Park B, Kim J, Park T . The genetic effect of copy number variations on the risk of type 2 diabetes in a Korean population. PLoS One. 2011; 6(4):e19091. PMC: 3081314. DOI: 10.1371/journal.pone.0019091. View

Craddock N, Hurles M, Cardin N, Pearson R, Plagnol V, Robson S . Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010; 464(7289):713-20. PMC: 2892339. DOI: 10.1038/nature08979. View

Kar S, Beesley J, Olama A, Michailidou K, Tyrer J, Kote-Jarai Z . Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discov. 2016; 6(9):1052-67. PMC: 5010513. DOI: 10.1158/2159-8290.CD-15-1227. View

10.

Song H, Cicek M, Dicks E, Harrington P, Ramus S, Cunningham J . The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014; 23(17):4703-9. PMC: 4119409. DOI: 10.1093/hmg/ddu172. View

11.

Phelan C, Kuchenbaecker K, Tyrer J, Kar S, Lawrenson K, Winham S . Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017; 49(5):680-691. PMC: 5612337. DOI: 10.1038/ng.3826. View

12.

Ascencio-Montiel I, Pinto D, Parra E, Valladares-Salgado A, Cruz M, Scherer S . Characterization of Large Copy Number Variation in Mexican Type 2 Diabetes subjects. Sci Rep. 2017; 7(1):17105. PMC: 5719030. DOI: 10.1038/s41598-017-17361-7. View

13.

. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet. 2000; 67(1):207-12. PMC: 1287079. View

14.

Pylkas K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, Winqvist R . Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network. PLoS Genet. 2012; 8(6):e1002734. PMC: 3380845. DOI: 10.1371/journal.pgen.1002734. View

15.

Gates M, Tworoger S, Terry K, De Vivo I, Hunter D, Hankinson S . Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations. Int J Cancer. 2008; 124(3):729-33. PMC: 2679694. DOI: 10.1002/ijc.23924. View

16.

Koolen D, Vissers L, Pfundt R, de Leeuw N, Knight S, Regan R . A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. Nat Genet. 2006; 38(9):999-1001. DOI: 10.1038/ng1853. View

17.

Long J, Delahanty R, Li G, Gao Y, Lu W, Cai Q . A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst. 2013; 105(8):573-9. PMC: 3627644. DOI: 10.1093/jnci/djt018. View

18.

Mancini-DiNardo D, Judkins T, Kidd J, Bernhisel R, Daniels C, Brown K . Detection of large rearrangements in a hereditary pan-cancer panel using next-generation sequencing. BMC Med Genomics. 2019; 12(1):138. PMC: 6798444. DOI: 10.1186/s12920-019-0587-3. View

19.

Kuusisto K, Akinrinade O, Vihinen M, Kankuri-Tammilehto M, Laasanen S, Schleutker J . copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer. PLoS One. 2013; 8(8):e71802. PMC: 3742470. DOI: 10.1371/journal.pone.0071802. View

20.

Lu Y, Ek W, Whiteman D, Vaughan T, Spurdle A, Easton D . Most common 'sporadic' cancers have a significant germline genetic component. Hum Mol Genet. 2014; 23(22):6112-8. PMC: 4271103. DOI: 10.1093/hmg/ddu312. View